NuWays AG Recommends Buying Eckert & Ziegler SE Stocks

NuWays AG has classified Eckert & Ziegler SE with a "BUY" recommendation, setting a target price of EUR 23. The first quarter results for 2026 are anticipated to show a 6% year-on-year sales growth to €72.5 million. However, the adjusted EBIT is expected to decline by 1% to €16.0 million, maintaining a 22.1% margin. The Medical segment, contributing 55% of sales, is projected to grow by 13% to €39.0 million, mainly driven by GalliaPharm's international expansion.

The Industrial Products segment is expected to decrease by 1% to €33.5 million. Although the recent oil price surge due to the Iran conflict has not yet translated into demand for IP products, growth remains promising in radiopharma. The radiopharma market is estimated to grow at approximately 15% annually into 2030, underscoring its importance in Eckert & Ziegler's growth trajectory. Despite a lack of current licence income, further revenues are anticipated later in the year.